Success Metrics

Clinical Success Rate

42.9%

Based on 3 completed trials

Completion Rate

43%(3/7)

Active Trials

0(0%)

Results Posted

133%(4 trials)

Terminated

4(50%)

Phase Distribution

Ph phase_2

13%

Ph early_phase_1

13%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 1Safety & dosage

6(75.0%)

Phase 2Efficacy & side effects

1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(5)

Detailed Status

Terminated4

Completed3

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

42.9%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (12.5%)

Phase 16 (75.0%)

Phase 21 (12.5%)

Trials by Status

completed338%

terminated450%

withdrawn113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_1

A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

NCT01877382

terminatedphase_2

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

NCT05932667

completedphase_1

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT03671564

withdrawnphase_1

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

NCT06090318

terminatedphase_1

A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

NCT05758818

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT01877382Phase 1

A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Completed

NCT05932667Phase 2

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Terminated

NCT03671564Phase 1

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed

NCT06090318Phase 1

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn

NCT05758818Phase 1

A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Terminated

NCT03552029Phase 1

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Terminated

NCT02319369Phase 1

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Terminated

NCT03614455Early Phase 1

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8